wildbird1 wrote: Thanks Camphikefish..I love it when peoples bring new treatments... it give us a chance to compare to TLT.
After googling N-803 & BCG, I found 2 quotes that are very interesting...
1) For N-803 & BCG...Eligibility criteria included histologically confirmed non-muscle invasive urothelial carcinoma of intermediate or high risk who had not received prior treatment with intravesical BCG.
Note 1: TLT treat patients that have receiced multiple BCG treatments, and that do not respond to any treatment at all anymore(End of the line patients).
2) Here is a Quote from Dr.Patrick Soon-Shiong, Chairman and CEO of ImmunityBio
(Quote) " We are pleased that the FDA has granted Breakthrough Therapy Designation to N-803 in combination with BCG for the treatment of patients with Non-Muscle Invasive Bladder Cancer with CIS (End of Quote).
Note:
With CIS....Approximately 10% of all Bladder cancer patients have Bladder cancer present with CIS.
TLT is way ahead of N-803 & BCG, for now TLT can only treat end of the line patients, but later as TLT progress ,TLT treatment could easily treat 100% of all Bladder Cancer patients without restrictions(not just 10%).
Camphikefish wrote: Hoping Enrique or someone can expand on the 72% CR ImmunityBio reported from their phase 2 150 + patient NMIBC trial as it relates to their current stock price . With so many patients disease free at 12 months it seems this stock would've gone sharply higher . I tried my best to research, read, and understand before this posting however, I realize I need to be enlightened ! Honestly I had never heard of this stock before someone posted about it yesterday or the day before . It concerns me . Please put me at ease !